Biocept rolls out liquid biopsy test for colorectal cancer; Sequenom struggles in Q2;

> Liquid biopsy outfit Biocept ($BIOC) launched its first diagnostic test for colorectal cancer. More

> Quanterix and Beth Israel Deaconess Medical Center are touting results from a new study showing the efficacy of Quanterix's Simoa technology in rapidly diagnosing C. difficile infections in stool samples. Statement

> Sequenom ($SQNM) stumbled during its second quarter, announcing revenues of $32.8 million--an 18% drop compared to the same quarter last year. More

> The Centers for Disease Control and Prevention (CDC) is funneling about $2.3 million in fiscal 2016 toward sequencing and bioinformatics technologies to fight infectious disease. Story (reg. req.)

> Exosome Diagnostics cut the ribbon on its Cambridge, MA-based CLIA-certified lab. Statement

And Finally… A new, video game-like tool for detecting early signs of Alzheimer's snagged marketing approval from the FDA. Story

Suggested Articles

The two companies also plan to identify new potential targets and therapeutic candidates for inflammatory bowel disease, or IBD.

This would allow centralized, lab-based diagnostic hardware to process blood samples at scale, screening patients for previous infections.

GlaxoSmithKline and AstraZeneca are considering forming a joint lab to help the U.K. expand its supplies for COVID-19 testing, according to Bloomberg.